
J&J Finalizes Intra-Cellular Therapies Acquisition, Strengthens Neuroscience Leadership
J&J Finalizes Intra-Cellular Therapies Acquisition, Strengthens Neuroscience Leadership Johnson & Johnson (NYSE: JNJ) has officially completed its acquisition of Intra-Cellular Therapies, Inc., marking a significant expansion of its neuroscience portfolio.…











